Skip to content
Uro-oncology · Robotic surgery · São PauloIn-person and telemedicine · WhatsApp (11) 99590-1506 · Tel. (11) 2769-3929
A Reference in Robotic Surgery · São Paulo

Robotic Surgery for Kidney Cancer

Da Vinci technology for treating kidney tumors with millimeter precision and maximum preservation of healthy kidney tissue.

Kidney Mass or Cyst: What Should You Do?

State-of-the-Art Robotic Nephrectomy

Partial Nephrectomy

Removal of the tumor only, preserving healthy kidney tissue. The gold standard for early-stage (T1) tumors.

Total Nephrectomy

Indicated for large tumors or tumors in complex locations. The robotic technique ensures less trauma and bleeding.

Faster Recovery

Hospital discharge within 24 to 48 hours in most cases, with a quick return to routine activities.

Patient Testimonials

★★★★★

“Dr. Bruno saved my kidney. I had a robotic partial nephrectomy and recovered very quickly. An extremely caring team.”

RM
Ricardo M.
Partial Nephrectomy Patient
★★★★★

“The robotic surgery went very smoothly. I felt practically no pain after the operation. I recommend it without hesitation.”

CS
Cláudia S.
Kidney Tumor Patient
★★★★★

“Grateful for all the reassurance I was given. Dr. Bruno is a reference both technically and as a human being. Having my surgery at Sírio was excellent.”

AF
Antônio F.
Robotic Surgery Patient
Dr. Bruno Benigno
Bruno Benigno - Doctoralia.com.br

Dr. Bruno Benigno

Specialized in uro-oncology and robotic surgery. With more than 1,500 robotic surgeries, he is a national reference in complex nephrectomy.

  • Experience
    15+ years in oncology practice
  • Training
    Master's in Oncology (A.C. Camargo)
  • Certification
    Da Vinci System Specialist
  • Active Member
    SBU, AUA and EAU
Request a Consultation on WhatsApp

Diagnosed with a kidney tumor? Book your consultation.

Do you have imaging tests suggesting a mass or cyst? Get an accurate diagnosis from a specialist in the field.

WhatsApp: (11) 99590-1506

Scientific references

The information on this page is based on the guidelines and studies below, published in peer-reviewed medical journals.

  1. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399-410. PubMed · DOI 10.1016/j.eururo.2022.03.006

    European (EAU) 2022 guideline on renal cell carcinoma: diagnosis, surgery and systemic treatment.

  2. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021;206(2):199-208. PubMed · DOI 10.1097/JU.0000000000001911

    American (AUA) guideline on the evaluation and management of renal masses and localized kidney cancer, including active surveillance and partial nephrectomy.

  3. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019;292(2):475-488. PubMed · DOI 10.1148/radiol.2019182646

    Bosniak classification, version 2019: estimates the risk of cancer in kidney cysts based on CT and MRI.

  4. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543-552. PubMed · DOI 10.1016/j.eururo.2010.12.013

    EORTC randomized trial comparing partial and radical nephrectomy in small renal tumors.

  5. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683-694. PubMed · DOI 10.1056/NEJMoa2106391

    KEYNOTE-564 trial: adjuvant pembrolizumab after nephrectomy reduced the risk of recurrence in patients at increased risk.

Medical content reviewed by Dr. Bruno Benigno, urologist and uro-oncologist (CRM-SP 126.265 · RQE 60022), based on AUA, EAU and NCCN guidelines. Last reviewed:

Book